|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 28, 2017 ) According to Publisher, the Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss.
For more information @ http://www.reportsweb.com/diabetic-retinopathy-treatment-global-market-outlook-2015-2022
North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region.
Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp.
Type of Treatments Covered:
- Intraocular Steroid Injection
- Vitrectomy
- Anti-Vascular Endothelial Growth Factor (VEGF) drug
- Laser Surgery
Disease Type Covered:
- Proliferative Diabetic Retinopathy (PDR)
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Moderate
- Mild
- Severe
End Users Covered:
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Hospitals
- Other End Users
Request Sample Copy http://www.reportsweb.com/inquiry&RW0001216339/sample
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- Rest of Asia Pacific
- Rest of the World
- Middle East
- Brazil
- Argentina
- South Africa
- Egypt
10 Company Profiling
10.1 Regeneron Pharmaceuticals Inc.
10.2 ThromboGenics
10.3 Genentech
10.4 Bayer Healthcare
10.5 Alimera Sciences
10.6 Actavis PLC
10.7 BCN Peptides
10.8 Novartis AG
10.9 Ampio Pharmaceuticals
10.10 Kowa Group
10.11 Sirnaomics Incorporation
10.12 Abbott Laboratories Ltd
10.13 Glycadia Pharmaceuticals
10.14 Alcon Laboratories Inc.
10.15 Parexel International Corp.
List of Tables
Make an enquiry: http://www.reportsweb.com/inquiry&RW0001216339/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
